Brii Biosciences Reports 2026 Interim Financials, Updates on HBV and Cancer Programs

Brii Biosciences announced its 2026 interim financial results alongside significant updates regarding its drug development pipeline. The company highlighted the progress of its hepatitis B (HBV) functional cure strategy, informed by topline data from Phase 2b studies. Further data from these studies is anticipated in the second half of 2026, which is expected to shape the company's ongoing research in this area.

The company is also advancing its oncology portfolio, with the BRII-5395 mRNA cancer vaccine slated for clinical evaluation in hepatocellular carcinoma (HCC). This move into clinical trials signifies a key step for the company's emerging discovery programs, which are reportedly building momentum.

Brii Biosciences stated that its strong cash position is supporting its strategic execution. The financial results and pipeline updates come at a time when significant investment and progress are needed to bring new therapies to market, particularly for challenging diseases like HBV and various forms of cancer.

The company's focus on HBV functional cure aims to address a significant unmet medical need. Concurrently, the development of mRNA cancer vaccines reflects the broader industry trend towards novel therapeutic modalities in oncology. Further details on the financial performance are expected to be released in subsequent filings.